Vulvar Cancer Treatment in India
Get Vulvar Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Vulvar Cancer Treatment in UAE
Vulvar Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Vulvar cancer treatment encompasses a spectrum of evidence-based interventions—including radical or modified radical vulvectomy, sentinel lymph node biopsy, intensity-modulated radiation therapy (IMRT), and platinum-based chemoradiation—tailored to disease stage and patient physiology. With five-year survival rates ranging from 70–90% for early-stage disease and 20–40% for advanced-stage disease depending on lymph node involvement, outcomes are highly institution- and surgeon-dependent, making specialist center selection critical. GAF Healthcare connects international patients with JCI- and NABH-accredited oncology centers in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, offering world-class gynecologic oncology expertise at a fraction of Western costs, with full end-to-end medical coordination.
Hospital Stay: 5–10 days (varies by surgical extent and reconstruction needs) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (dependent on wound healing, lymphedema status, and adjuvant therapy completion) • Success Rate: 70–90% (5-year survival for Stage I–II; stage-dependent)
What Is It?
Vulvar cancer is a malignancy arising from the squamous epithelium of the external female genitalia, accounting for approximately 4–5% of all gynecologic cancers globally. The vast majority—around 90%—are squamous cell carcinomas (SCC), with the remainder comprising melanomas, adenocarcinomas of Bartholin's gland, basal cell carcinomas, and rare sarcomas. Two distinct pathogenic pathways are recognized: the HPV-associated pathway, predominantly affecting younger women and linked to vulvar intraepithelial neoplasia (VIN), and the HPV-independent pathway occurring in older women with a background of lichen sclerosus or differentiated VIN. Physiologically, the disease carries significant functional and psychosexual implications, as surgical intervention may alter urinary, bowel, and sexual function, necessitating a holistic multidisciplinary approach.
Disease staging follows the FIGO 2021 classification system, which integrates tumor size, depth of invasion, lymph node status (including extracapsular spread and the number of positive nodes), and the presence of distant metastasis. Inguinofemoral lymph node involvement is the single most powerful prognostic determinant: patients with node-negative disease achieve 5-year survival rates exceeding 90%, which falls to approximately 50–60% with 1–2 positive nodes and to below 25% with three or more involved nodes. Surgical margin status is equally critical—a minimum of 8 mm clear margin (measured on the fixed specimen) is the accepted oncologic standard to minimize local recurrence risk.
The current standard of care is multimodal and individualized. Early-stage disease (FIGO IA–IB) is primarily managed with wide local excision or radical local excision combined with sentinel lymph node biopsy (SLNB) using technetium-99m and/or blue dye mapping. Locally advanced or node-positive disease is treated with definitive or adjuvant chemoradiation—typically concurrent cisplatin or 5-fluorouracil with intensity-modulated radiation therapy (IMRT) to reduce dose to adjacent organs. Recurrent or metastatic disease may be candidates for immune checkpoint inhibitor therapy (pembrolizumab under FDA/EMA approval in specific PD-L1-positive or TMB-high populations) or targeted agents where molecular profiling supports their use. Plastic and reconstructive procedures—including myocutaneous flaps such as the vertical rectus abdominis myocutaneous (VRAM) flap or the lotus petal flap—are integral to surgical planning in cases requiring extensive resection.
Candidates
• Confirmed histopathological diagnosis of vulvar malignancy (squamous cell carcinoma, melanoma, Bartholin gland adenocarcinoma, or other subtypes) via punch or incisional biopsy
• FIGO Stage I–IVA disease considered for curative-intent surgery or definitive chemoradiation
• FIGO Stage IVB or recurrent/metastatic disease considered for systemic therapy, palliative radiation, or clinical trial enrollment
• Patients with HPV-associated VIN3 or differentiated VIN with high-risk features (multifocal disease, prior treatment failure)
• Required pre-treatment diagnostics:
- MRI pelvis with contrast (to assess depth of invasion, urethral/anal proximity, and lymph node morphology)
- PET-CT scan (whole body, for nodal and distant metastasis staging in Stage IB and above)
- CT chest/abdomen/pelvis with contrast (if PET-CT unavailable or to supplement)
- Sentinel lymph node mapping evaluation (for early-stage eligible patients)
- HPV genotyping and p16 immunohistochemistry on biopsy specimen
- Complete blood count, renal and liver function panels, coagulation profile
- Serum SCC antigen (squamous cell carcinoma antigen) as baseline tumor marker
- Electrocardiogram (ECG) and echocardiogram (ECHO) if cisplatin-based chemotherapy is planned
- Pulmonary function tests (PFTs) if extensive radiation field is anticipated
- Nutritional assessment and prehabilitation evaluation
- Gynecologic oncology, radiation oncology, and medical oncology multidisciplinary tumor board review
• Contraindications and relative exclusions:
- Uncontrolled systemic illness (decompensated cardiac failure, active hepatic failure) precluding anesthesia or chemotherapy
- Active autoimmune disease or long-term immunosuppressant use (relative contraindication to checkpoint inhibitor therapy)
- Pregnancy (requires individualized multidisciplinary counseling)
- Prior pelvic radiation exceeding tolerance doses (limits further radiation options)
- Patient refusal of blood products (requires informed surgical planning)
- Severe peripheral vascular disease or lymphedema significantly elevating surgical wound complication risk
Procedure
SURGICAL APPROACHES:
1. Wide Local Excision (WLE) / Radical Local Excision: The standard for FIGO Stage IA (invasion ≤1 mm) involves WLE with 1 cm clinical margins. For Stage IB–II, radical local excision targets an 8 mm pathologic margin. The "three-incision" technique has replaced the classical butterfly incision for inguinofemoral lymphadenectomy, significantly reducing wound complication rates from ~50% to under 20%.
2. Sentinel Lymph Node Biopsy (SLNB): Validated by the GROINSS-V and GOG-173 trials, SLNB using a combination of technetium-99m radiocolloid and isosulfan blue or patent blue V dye—or increasingly, indocyanine green (ICG) with near-infrared (NIR) fluorescence imaging—is the standard of care for unifocal tumors <4 cm with clinically node-negative groins. Ultrastaging of sentinel nodes using serial sectioning and cytokeratin immunohistochemistry maximizes sensitivity. GROINSS-V II data support omission of full groin lymphadenectomy in patients with low-volume sentinel node metastasis (<2 mm), replacing it with concurrent chemoradiation.
3. Inguinofemoral Lymphadenectomy (IFL): Indicated when SLNB is not feasible (multifocal tumor, prior groin surgery, or failed sentinel node mapping) or when sentinel nodes are positive with macrometastasis. Superficial and deep femoral nodal dissection is performed. Sartorius muscle transposition over the femoral vessels reduces post-operative wound breakdown risk.
4. Radical Vulvectomy: Reserved for centrally advanced tumors requiring en-bloc resection. Skin-sparing and nerve-sparing modifications are employed where oncologically safe to preserve clitoral sensation and pelvic floor function.
5. Reconstructive Flap Surgery: Extensive resections mandating primary closure under tension utilize reconstructive options including the lotus petal fasciocutaneous flap, the pudendal thigh flap, or the VRAM (vertical rectus abdominis myocutaneous) flap. Plastic surgery co-management is essential for wound integrity and functional outcome.
6. Robotic-Assisted and Minimally Invasive Surgery: Robotic-assisted lymphadenectomy using the da Vinci surgical system is offered at select advanced centers for pelvic and para-aortic nodal staging in cases with concurrent endometrial or cervical pathology, or for extraperitoneal groin dissection in selected patients, reducing blood loss and recovery time.
RADIATION THERAPY APPROACHES:
1. Intensity-Modulated Radiation Therapy (IMRT): The current gold standard for adjuvant and definitive external beam radiation. IMRT delivers conformal high-dose radiation to the vulva, groins, and pelvic nodes while using inverse-planned dose constraints to spare the bladder, rectum, and femoral heads. Typical doses: 45–50.4 Gy to regional nodes; 54–64 Gy to gross disease in definitive settings.
2. Stereotactic Body Radiation Therapy (SBRT): Used for oligometastatic disease or as a boost technique to the primary tumor or positive nodes in selected cases.
3. Brachytherapy: High-dose-rate (HDR) intracavitary or interstitial brachytherapy is used as a tumor boost in patients with close or positive surgical margins who are not candidates for re-excision.
SYSTEMIC THERAPY:
1. Concurrent Chemoradiation: Cisplatin (40 mg/m² weekly) concurrent with IMRT is the standard regimen for locally advanced (Stage III–IVA) or high-risk adjuvant settings. The 5-fluorouracil + mitomycin-C doublet is an alternative with established efficacy from anal cancer literature, used in some center protocols.
2. Immune Checkpoint Inhibitors: Pembrolizumab (anti-PD-1) has received accelerated FDA approval for PD-L1-positive (CPS ≥10) unresectable or recurrent vulvar SCC not amenable to curative surgery or radiation, based on KEYNOTE-158 basket trial data. Nivolumab and dostarlimab are under investigation.
3. Targeted Therapy and Molecular Profiling: Next-generation sequencing (NGS) of tumor tissue (e.g., FoundationOne CDx or equivalent) identifies actionable mutations including EGFR amplification, PIK3CA mutations, CDKN2A loss, and ERBB2 amplification. Patients with TMB-high or MSI-high tumors benefit from checkpoint blockade regardless of histology (pembrolizumab tumor-agnostic approval). VEGFR-targeted agents (bevacizumab, pazopanib) are explored in recurrent disease.
4. Neoadjuvant Chemotherapy/Chemoradiation: Used to downstage borderline-resectable tumors involving the urethra or anus, converting initially inoperable disease to resectable with organ preservation intent.
SUPPORTIVE AND INTEGRATIVE ONCOLOGY:
• Lymphedema prevention protocols including pneumatic compression, manual lymphatic drainage, and compression garments initiated perioperatively
• Sexual rehabilitation and pelvic floor physiotherapy programs
• Psycho-oncology support and body image counseling
• Nutritional optimization pre- and post-treatment
Cost of Vulvar Cancer Treatment: India vs. UAE
The cost of vulvar cancer treatment varies considerably based on disease stage, surgical complexity, the need for reconstructive procedures, and whether adjuvant chemoradiation is required. Both India and the UAE offer internationally accredited centers with fellowship-trained gynecologic oncologists; however, India delivers substantially lower costs—typically 40–60% less than the UAE—without compromising oncologic outcomes or infrastructure quality. The estimates below reflect surgery-inclusive packages; adjuvant radiation (IMRT) and chemotherapy cycles are billed additionally and are itemized transparently by GAF Healthcare prior to commitment.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,000 – $14,000 | ~51% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $9,000 – $28,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-ARRIVAL PHASE (2–4 weeks before travel):
• GAF Healthcare coordinator contacts the patient and reviews all existing medical records, biopsy reports, imaging, and pathology
• Records are transmitted to the assigned gynecologic oncologist for virtual multidisciplinary tumor board review
• A preliminary treatment plan and cost estimate are provided within 48–72 hours
• e-Medical visa application initiated for India-bound patients (typically processed in 3–5 business days); UAE entry visa or visa-on-arrival facilitated for UAE-bound patients
• Prehabilitation guidance issued: nutritional optimization, iron supplementation if anemic, smoking cessation protocol, and pre-operative pelvic floor physiotherapy instructions
ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3):
• Airport pickup by GAF Healthcare concierge; transfer to partner hospital or affiliated accommodation
• Day 1–2: Comprehensive oncology consultation with lead gynecologic oncologist; staging confirmed or updated with local imaging (MRI pelvis, PET-CT) if not recently performed or technically adequate
• Multidisciplinary tumor board review with gynecologic oncology, radiation oncology, medical oncology, reconstructive surgery, anesthesiology, and supportive care teams
• Anesthesia pre-assessment, baseline ECHO if chemo planned, nutritional and physiotherapy baseline assessment
• Sentinel lymph node mapping nuclear medicine injection (if SLNB planned) performed Day 2 or Day of Surgery
• Informed consent process with medical interpreter if required; final treatment plan confirmed with patient
SURGICAL INTERVENTION (Day 3–4):
• Procedure performed under general anesthesia; operative duration ranges from 2 hours (wide local excision + SLNB) to 6–8 hours (radical vulvectomy with flap reconstruction)
• Intraoperative: gamma probe-guided sentinel node identification, frozen section analysis of sentinel nodes, and margin assessment
• If radical resection with reconstruction: plastic surgery team performs flap harvest and inset simultaneously
• Post-operatively: patient transferred to high-dependency unit (HDU) or gynecologic oncology ward; Jackson-Pratt surgical drains placed in groin wounds
ACUTE INPATIENT RECOVERY (Days 4–10):
• Day 1–2 post-op: ambulation with physiotherapy guidance; Foley catheter in situ (retained 7–14 days post radical vulvectomy); drain output monitored daily
• Day 2–4 post-op: oral intake resumed; wound inspection; lymphorrhea or seroma management initiated
• Drain removal when output <30–50 mL/24h (typically Day 5–10)
• Surgical pathology report issued within 5–7 business days; final stage, margin status, and nodal status reviewed
• If adjuvant therapy indicated, radiation and/or chemotherapy planning CT simulation scheduled prior to discharge
• Discharge planning: wound care education, compression garment fitting, lymphedema physiotherapy initiated, outpatient follow-up scheduled
POST-DISCHARGE / IN-COUNTRY RECOVERY (Weeks 2–6):
• Patients remain in-country for wound surveillance (typically at Day 14 for suture/staple removal)
• If adjuvant chemoradiation is required: 5–6 week IMRT course with weekly cisplatin initiated 4–6 weeks post-operatively; patients must remain in-country during radiation
• Lymphedema physiotherapy sessions 2–3 times per week
• Pelvic floor physiotherapy and psychosexual counseling initiated
• Repeat wound assessment and oncology review at 4–6 weeks
FIT-TO-FLY ASSESSMENT (Weeks 4–8):
• For surgery-only patients with no adjuvant therapy: fit-to-fly assessment at 4–6 weeks post-operatively; prerequisites include fully healed perineal wound without dehiscence, controlled lymphorrhea, stable hemoglobin, and ability to mobilize safely
• For patients completing chemoradiation: fit-to-fly assessment 2–4 weeks after completion of radiation; radiation-related acute dermatitis and mucositis must be resolving
• GAF Healthcare coordinator obtains formal medical fitness-to-fly letter from treating physician
• Compression garment prescription and in-flight lymphedema protocol provided
• Detailed summary records, pathology reports, operative notes, and radiation dose summaries provided for the patient's home oncologist
LONG-TERM FOLLOW-UP PROTOCOL:
• GAF Healthcare facilitates teleconsultation follow-up at 3, 6, and 12 months post-treatment
• Surveillance: clinical examination every 3 months for 2 years, then every 6 months to Year 5; MRI or PET-CT at 3 months post-treatment and annually if clinically indicated
• HPV vaccination counseling for younger patients with HPV-associated disease
Risks & Considerations
Vulvar cancer treatment carries procedure-specific risks that patients must understand to make informed decisions. Surgically, inguinofemoral wound breakdown remains the most frequent complication, occurring in 15–30% of cases even with the three-incision technique; risk is compounded by obesity, diabetes, and prior radiation. Lymphedema of the lower extremities is a chronic, potentially lifelong complication reported in 30–70% of patients undergoing full groin lymphadenectomy; SLNB significantly reduces but does not eliminate this risk. Prolonged urinary catheterization after radical vulvectomy carries urinary tract infection and bladder dysfunction risk. Sexual dysfunction—including dyspareunia, altered body image, and loss of clitoral sensation—is common and requires proactive psychosexual rehabilitation. For chemoradiation, acute toxicities include cisplatin-related nephrotoxicity (mitigated by aggressive IV hydration), radiation-induced moist desquamation of the perineal skin and mucosae, fatigue, and hematologic suppression. Late radiation effects include vaginal stenosis, fibrosis, secondary lymphedema, and rarely, radiation proctitis or cystitis. Immunotherapy with pembrolizumab introduces immune-related adverse events (irAEs) including dermatitis, colitis, pneumonitis, endocrinopathies (hypothyroidism, adrenal insufficiency), and rare fulminant myocarditis—all requiring corticosteroid management and potentially treatment discontinuation. Oncologically, local recurrence rates of 15–40% are reported for advanced-stage disease and close-margin resections, underscoring the importance of treating at high-volume specialist centers with rigorous margin assessment protocols. Patients with significant comorbidities—particularly cardiovascular disease, renal impairment, or prior pelvic surgery—require thorough pre-treatment risk stratification, which GAF Healthcare facilitates through its multidisciplinary pre-arrival review process.
Top Hospitals for Vulvar Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Vulvar Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Vinod Raina
MBBS, MD (Internal Medicine), DM (Medical Oncology), Fellowship, Fellowship
Medical Oncologist
Fortis Memorial Research Institute, Gurgaon, India
40+ Yearsof experience
Dr. Vinod Raina is a distinguished figure in the field of Medical Oncology in India, with over 40 years of exemplary experience. He is currently associated with Fortis Memorial Research Institute in Gurugram, where he functions as the Chairman and Head of Medical Oncology and Hematology. His primary expertise lies in chemotherapy treatment and he was the first to perform high-dose chemotherapy in India. He also performed the first peripheral blood BMT in… Read more
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Ashwin Sunil Tamhankar
MBBS, MS, MCh Urology, DNB Urology, Vattikuti Robotic Uro-oncology Fellowship, RCS Laser Urological Robotic Fellowship, Olympus Laparoscopic Endo-Urology Fellowship
Surgical Oncologist & Robotic Uro-Oncologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Ashwin Sunil Tamhankar is a Consultant in Surgical Oncology and Robotic Surgery based at Apollo Hospitals in Navi Mumbai, India. With over 9 years of specialized experience, he has established himself as a leading uro-oncologist, combining advanced robotic surgical techniques with precision cancer care. His credentials include MBBS, MS, MCh Urology, DNB Urology, and prestigious fellowships from the Vattikuti Institute, Royal College of Surgeons of… Read more
Dr. Asit Arora
MBBS, MS, MCh
GI & HPB Surgical Oncologist
Indraprastha Apollo Hospital, New Delhi, India
22+ Yearsof experience
Dr. Asit Arora is a Clinical Lead in GI and HPB Surgical Oncology at Indraprastha Apollo Hospital, New Delhi, bringing over 22 years of specialized expertise in managing complex gastrointestinal and hepatobiliary cancers. He holds an MBBS, MS in General Surgery, and an MCh in Gastrointestinal Surgery, and is widely recognized across India and internationally for his precision in radical oncologic resections and advanced abdominal cancer surgery. Dr. Arora… Read more
Dr. B. Niranjan Naik
MBBS, MS, Onco-Surgery, FIAGES
Surgical Oncologist
Paras Hospitals, Gurugram, India
22+ Yearsof experience
Dr. B. Niranjan Naik is Principal Director of Surgical Oncology and Director of Breast & Gastro-Intestinal Onco-Surgery at Paras Hospitals in Gurugram. With over 22 years of distinguished clinical experience, he is widely recognized as one of the leading breast cancer surgeons in the Delhi and Gurugram region. His credentials include MBBS and MS (General Surgery) from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by specialized… Read more
Frequently Asked Questions — Vulvar Cancer Treatment
The total cost of vulvar cancer treatment in India typically ranges from USD 4,000 to USD 14,000, depending on the stage of disease, the type of surgery required (wide local excision versus radical vulvectomy with flap reconstruction), the need for sentinel lymph node biopsy, and whether adjuvant chemoradiation is included. In the UAE (Dubai or Abu Dhabi), the equivalent treatment package costs approximately USD 9,000 to USD 28,000, reflecting higher operational costs, luxury hospital infrastructure, and premium nursing ratios. India is generally 40–60% more cost-effective than the UAE. Both destinations offer JCI-accredited hospitals and fellowship-trained gynecologic oncologists with international patient volumes. Adjuvant IMRT radiation (5–6 weeks) and weekly cisplatin chemotherapy cycles are priced additionally; GAF Healthcare provides a fully itemized, stage-specific cost estimate prior to any financial commitment, with no hidden fees.
The minimum in-country stay before being medically cleared to fly home depends on the treatment received. For patients undergoing surgical resection alone (wide local excision or radical vulvectomy with sentinel lymph node biopsy, without adjuvant therapy), the typical fit-to-fly window is 4–6 weeks post-operatively. This timeline allows for complete perineal wound healing, drain removal, suture removal at Day 14, physiotherapy initiation for lymphedema prevention, and a formal oncology review of the final pathology report to confirm the treatment plan. For patients requiring adjuvant concurrent chemoradiation (typically a 5–6 week IMRT course beginning 4–6 weeks post-surgery), the total in-country stay extends to 10–14 weeks. Flying before wound healing is complete carries risks of deep vein thrombosis (DVT), wound dehiscence due to cabin pressure changes, and lymphatic fluid shifts exacerbating early lymphedema. A formal medical fitness-to-fly letter is issued by the treating gynecologic oncologist before departure, and GAF Healthcare provides in-flight compression garment prescriptions and DVT prophylaxis guidance for all patients.
The success rate of vulvar cancer treatment is strongly stage-dependent and is best expressed as the 5-year overall survival rate. For FIGO Stage I disease (tumor confined to the vulva with negative lymph nodes), 5-year survival exceeds 90%. For Stage II (tumor spread to adjacent perineal structures with negative nodes), survival ranges from 75–85%. Stage III disease (inguinofemoral lymph node involvement) carries a 5-year survival of 40–65%, with outcomes worsening as the number of involved nodes and the presence of extracapsular spread increase. Stage IVA disease (involving the proximal urethra, bladder mucosa, rectal mucosa, or pelvic bone) achieves 5-year survival rates of 20–40% with aggressive multimodal therapy. Stage IVB (distant metastasis) has a median survival of 12–18 months with modern systemic therapies, including pembrolizumab in PD-L1-positive tumors. These outcomes are achievable at high-volume gynecologic oncology centers in both India and the UAE, where GAF Healthcare's network partners demonstrate tumor board-reviewed, protocol-driven care with surgical case volumes that meet international benchmarks for outcome optimization.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive non-medical support to ensure that international patients travelling to India or the UAE for vulvar cancer treatment experience no logistical barriers to accessing world-class oncologic care.
VISA & ENTRY FACILITATION: For India-bound patients, GAF Healthcare initiates and guides the e-Medical Visa (e-MV) application, which permits stays of up to 60 days per visit (extendable) and allows one accompanying attendant on an e-Medical Attendant Visa. Processing typically takes 3–5 business days; GAF's coordinators provide the hospital invitation letter and all documentation required by the Indian embassy portal. For UAE-bound patients (Dubai or Abu Dhabi), nationals of over 50 countries benefit from visa-on-arrival or visa-free entry. GAF facilitates medical visit visas for other nationalities through hospital-sponsored visa applications and liaises directly with DHA-licensed facility administrations for expedited approvals.
AIRPORT TRANSFERS & GROUND LOGISTICS: Dedicated, wheelchair-accessible airport transfers are arranged for arrival and departure, with a GAF-assigned patient coordinator present at the airport to escort the patient directly to the hospital or partner accommodation. All inter-facility transfers (e.g., between diagnostic center and hospital) are coordinated seamlessly.
MEDICAL INTERPRETATION & COMMUNICATION: Certified medical interpreters are available in Arabic, Russian, French, Swahili, and other languages for all clinical consultations, informed consent discussions, and post-operative counseling. Written discharge summaries and operative notes are translated into the patient's language upon request.
ACCOMMODATION FOR ATTENDANTS: GAF Healthcare has pre-negotiated rates at partner serviced apartments and hotels adjacent to all network hospitals, ranging from economy to premium tiers. Attendant accommodation packages—including meals and local transport—can be bundled into the treatment package for transparent, upfront pricing. For patients requiring extended stays during adjuvant radiation (5–6 weeks), fully furnished apartment options with kitchen facilities are arranged at discounted long-stay rates.
TELEMEDICINE & POST-DEPARTURE CARE COORDINATION: Following return to the home country, GAF Healthcare's care coordination team facilitates secure video consultations between the patient and their treating gynecologic oncologist, transmits all medical records to the patient's home physician, and coordinates re-imaging or laboratory follow-up requests across borders. Emergency medical helpline access is provided 24/7 during the patient's entire in-country stay.
Patients Also Explore
Other treatments commonly sought by patients considering Vulvar Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology